|
1
|
Boyle WJ, Simonet WS and Lacey DL:
Osteoclast differentiation and activation. Nature. 423:337–342.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Seeman E and Delmas PD: Bone quality-the
material and structural basis of bone strength and fragility. N
Engl J Med. 354:2250–2261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
An J, Yang H, Zhang Q, Liu C, Zhao J,
Zhang L and Chen B: Natural products for treatment of osteoporosis:
The effects and mechanisms on promoting osteoblast-mediated bone
formation. Life Sci. 147:46–58. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Manolagas SC, O'Brien CA and Almeida M:
The role of estrogen and androgen receptors in bone health and
disease. Nat Rev Endocrinol. 9:699–712. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Onal M, Xiong J, Chen X, Thostenson JD,
Almeida M, Manolagas SC and O'Brien CA: Receptor activator of
nuclear factor κB ligand (RANKL) protein expression by B
lymphocytes contributes to ovariectomy-induced bone loss. J Biol
Chem. 287:29851–29860. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arai F, Miyamoto T, Ohneda O, Inada T,
Sudo T, Brasel K, Miyata T, Anderson DM and Suda T: Commitment and
differentiation of osteoclast precursor cells by the sequential
expression of c-Fms and receptor activator of nuclear factor kappaB
(RANK) receptors. J Exp Med. 190:1741–1754. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lacey DL, Timms E, Tan HL, Kelley MJ,
Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S,
et al: Osteoprotegerin ligand is a cytokine that regulates
osteoclast differentiation and activation. Cell. 93:165–176. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gu DR, Lee JN, Oh GS, Kim HJ, Kim MS and
Lee SH: The inhibitory effect of beta-lapachone on RANKL-induced
osteoclastogenesis. Biochem Biophys Res Commun. 482:1073–1079.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wagner EF and Eferl R: Fos/AP-1 proteins
in bone and the immune system. Immunol Rev. 208:126–140. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng
C, Qiu W, Wu X, Wang X, Li H, et al: Maslinic acid suppresses
osteoclastogenesis and prevents ovariectomy-induced bone loss by
regulating RANKL-mediated NF-κB and MAPK signaling pathways. J Bone
Miner Res. 26:644–656. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takayanagi H: The role of NFAT in
osteoclast formation. Ann N Y Acad Sci. 1116:227–237. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Conaway HH, Henning P, Lie A, Tuckermann J
and Lerner UH: Activation of dimeric glucocorticoid receptors in
osteoclast progenitors potentiates RANKL induced mature osteoclast
bone resorbing activity. Bone. 93:43–54. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kohno M, Aikawa Y, Tsubouchi Y,
Hashiramoto A, Yamada R, Kawahito Y, Inoue K, Kusaka Y, Kondo M and
Sano H: Inhibitory effect of T-614 on tumor necrosis factor-alpha
induced cytokine production and nuclear factor-kappaB activation in
cultured human synovial cells. J Rheumatol. 28:2591–2596.
2001.PubMed/NCBI
|
|
14
|
Kawakami A, Tsuboi M, Urayama S, Matsuoka
N, Yamasaki S, Hida A, Aoyagi T, Furuichi I, Nakashima T, Migita K,
et al: Inhibitory effect of a new anti-rheumatic drug T-614 on
costimulatory molecule expression, cytokine production, and antigen
presentation by synovial cells. J Lab Clin Med. 133:566–574. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Du F, Lü LJ, Fu Q, Dai M, Teng JL, Fan W,
Chen SL, Ye P, Shen N, Huang XF, et al: T-614, a novel
immunomodulator, attenuates joint inflammation and articular damage
in collagen-induced arthritis. Arthritis Res Ther. 10:R1362008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wan Y, Chong LW and Evans RM: PPAR-gamma
regulates osteoclastogenesis in mice. Nat Med. 13:1496–1503. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Luo Q, Sun Y, Liu W, Qian C, Jin B, Tao F,
Gu Y, Wu X, Shen Y and Xu Q: A novel disease-modifying
antirheumatic drug, iguratimod, ameliorates murine arthritis by
blocking IL-17 signaling, distinct from methotrexate and
leflunomide. J Immunol. 191:4969–4978. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fan H, Ji F, Lin Y, Zhang M, Qin W, Zhou Q
and Wu Q: Electroacupuncture stimulation at CV4 prevents
ovariectomy-induced osteoporosis in rats via Wnt-β-catenin
signaling. Mol Med Rep. 13:2485–2491. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen Y, Wang XX, Zhao BJ, Bu J, Su YR and
Zhang J: Effects of icariin on orthodontic tooth movement in rats.
Int J Clin Exp Med. 8:8608–8616. 2015.PubMed/NCBI
|
|
20
|
Koga T, Inui M, Inoue K, Kim S, Suematsu
A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, et al:
Costimulatory signals mediated by the ITAM motif cooperate with
RANKL for bone homeostasis. Nature. 428:758–763. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Guan H, Li J, Fang Z, Chen W and
Li F: Amlexanox suppresses osteoclastogenesis and prevents
ovariectomy-induced bone loss. Sci Rep. 5:135752015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang X, Zhu Y, Zheng S, Ni C, Zhao L, Liu
C, Chen A and Xiao J: Amiloride inhibits osteoclastogenesis by
suppressing nuclear factor-κB and mitogen-activated protein kinase
activity in receptor activator of nuclear factor-κB-induced
RAW264.7 cells. Mol Med Rep. 11:3451–3456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guan H, Zhao L, Cao H, Chen A and Xiao J:
Epoxyeicosanoids suppress osteoclastogenesis and prevent
ovariectomy-induced bone loss. FASEB J. 29:1092–1101. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cline-Smith A, Gibbs J, Shashkova E,
Buchwald ZS, Novack DV and Aurora R: Pulsed low-dose RANKL as a
potential therapeutic for postmenopausal osteoporosis. JCI Insight.
1:e888392016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun Y, Ye DW, Zhang P, Wu YX, Wang BY,
Peng G and Yu SY: Anti-rheumatic drug iguratimod (T-614) alleviates
cancer-induced bone destruction via down-regulating interleukin-6
production in a nuclear factor-κB-dependent manner. J Huazhong Univ
Sci Technolog Med Sci. 36:691–699. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Käkönen SM and Mundy GR: Mechanisms of
osteolytic bone metastases in breast carcinoma. Cancer. 97 Suppl
3:S834–S839. 2003. View Article : Google Scholar
|
|
27
|
Roodman GD: Genes associate with abnormal
bone cell activity in bone metastasis. Cancer Metastasis Rev.
31:569–578. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jilka RL, Hangoc G, Girasole G, Passeri G,
Williams DC, Abrams JS, Boyce B, Broxmeyer H and Manolagas SC:
Increased osteoclast development after estrogen loss: Mediation by
interleukin-6. Science. 257:88–91. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Asagiri M and Takayanagi H: The molecular
understanding of osteoclast differentiation. Bone. 40:251–264.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ortega N, Behonick D, Stickens D and Werb
Z: How proteases regulate bone morphogenesis. Ann N Y Acad Sci.
995:109–116. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bu S, Chen Y, Wang S, Zhang F and Ji G:
Treadmill training regulates β-catenin signaling through
phosphorylation of GSK-3β in lumbar vertebrae of ovariectomized
rats. Eur J Appl Physiol. 112:3295–3304. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li GW, Xu Z, Chang SX, Nian H, Wang XY and
Qin LD: Icariin prevents ovariectomy-induced bone loss and lowers
marrow adipogenesis. Menopause. 21:1007–1016. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sottile V, Seuwen K and Kneissel M:
Enhanced marrow adipogenesis and bone resorption in
estrogen-deprived rats treated with the PPARgamma agonist BRL49653
(rosiglitazone). Calcif Tissue Int. 75:329–337. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gan K, Yang L, Xu L, Feng X, Zhang Q, Wang
F, Tan W and Zhang M: Iguratimod (T-614) suppresses RANKL-induced
osteoclast differentiation and migration in RAW264.7 cells via
NF-κB and MAPK pathways. Int Immunopharmacol. 35:294–300. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang XT, Li P, Xu TS, Ding R, Zhang X and
Bi LQ: Effect of iguratimod and methotrexate on RANKL and OPG
expression in serum and IL-1β-induced fibroblast-like synoviocytes
from patients with rheumatoid arthritis. Cell Mol Biol
(Noisy-le-grand). 62:44–50. 2016. View Article : Google Scholar
|
|
36
|
Okamura K, Yonemoto Y, Suto T, Okura C and
Takagishi K: Efficacy at 52 weeks of daily clinical use of
iguratimod in patients with rheumatoid arthritis. Mod Rheumatol.
25:534–539. 2015. View Article : Google Scholar : PubMed/NCBI
|
